Is intralymphatic immunotherapy effective and safe for allergic rhinitis?: A meta-analysis.

IF 1.3 4区医学 Q2 MEDICINE, GENERAL & INTERNAL

Medicine Pub Date : 2024-11-15 DOI:10.1097/MD.0000000000040589

Liangrong Liu, Yacheng Liang, Le Yan, Zhiyong Li

{"title":"Is intralymphatic immunotherapy effective and safe for allergic rhinitis?: A meta-analysis.","authors":"Liangrong Liu, Yacheng Liang, Le Yan, Zhiyong Li","doi":"10.1097/MD.0000000000040589","DOIUrl":null,"url":null,"abstract":"Background: As there is much controversy in using intralymphatic immunotherapy (ILIT) as a therapeutic means for allergic rhinitis (AR), its efficacy and safety for AR were investigated based on a systematic review and meta-analysis.Methods: Databases PubMed, Embase, Cochrane library, and Web of Science were employed to retrieve relevant randomized control studies on ILIT for AR. The search deadline was September 15, 2023. Meta-analysis was performed on the data of the included literature using Stata 15.0.Results: Eleven randomized control studies were included involving a total of 406 patients. Meta-analysis results revealed that ILIT improved patients' quality of life [standardized mean difference (SMD) = -0.53, 95% confidence interval (CI) = (-1.00, -0.050)], and reduced the adverse events of nasal symptoms [risk ratio (RR) = 0.16, 95% CI = (0.06, 0.45)] as compared to control, whereas no significant difference was discovered in symptom score [SMD = 0.14, 95% CI = (-0.34, 0.62)], IgE [SMD = 0.93, 95% CI = (-0.44, 2.30)], medication scores [SMD = 1.37, 95% CI = (-0.45, 3.18)], comprehensive symptom and medication scores [SMD = 0.93, 95% CI = (-0.62, 2.47)], nasal symptoms [RR = 0.16, 95% CI = (0.06, 0.45)], and lymphadenectasis [RR = 2.27, 95% CI = (0.37, 6.73)] versus control.Conclusion: After the application of the ILIT strategy against AR, the quality of life of patients was improved and the incidence of adverse events associated with nasal symptoms was reduced, but the conclusion needed further verification with more high-quality research.","PeriodicalId":18549,"journal":{"name":"Medicine","volume":"103 46","pages":"e40589"},"PeriodicalIF":1.3000,"publicationDate":"2024-11-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11576000/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Medicine","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1097/MD.0000000000040589","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"MEDICINE, GENERAL & INTERNAL","Score":null,"Total":0}

引用次数: 0

Abstract

Background: As there is much controversy in using intralymphatic immunotherapy (ILIT) as a therapeutic means for allergic rhinitis (AR), its efficacy and safety for AR were investigated based on a systematic review and meta-analysis.

Methods: Databases PubMed, Embase, Cochrane library, and Web of Science were employed to retrieve relevant randomized control studies on ILIT for AR. The search deadline was September 15, 2023. Meta-analysis was performed on the data of the included literature using Stata 15.0.

Results: Eleven randomized control studies were included involving a total of 406 patients. Meta-analysis results revealed that ILIT improved patients' quality of life [standardized mean difference (SMD) = -0.53, 95% confidence interval (CI) = (-1.00, -0.050)], and reduced the adverse events of nasal symptoms [risk ratio (RR) = 0.16, 95% CI = (0.06, 0.45)] as compared to control, whereas no significant difference was discovered in symptom score [SMD = 0.14, 95% CI = (-0.34, 0.62)], IgE [SMD = 0.93, 95% CI = (-0.44, 2.30)], medication scores [SMD = 1.37, 95% CI = (-0.45, 3.18)], comprehensive symptom and medication scores [SMD = 0.93, 95% CI = (-0.62, 2.47)], nasal symptoms [RR = 0.16, 95% CI = (0.06, 0.45)], and lymphadenectasis [RR = 2.27, 95% CI = (0.37, 6.73)] versus control.

Conclusion: After the application of the ILIT strategy against AR, the quality of life of patients was improved and the incidence of adverse events associated with nasal symptoms was reduced, but the conclusion needed further verification with more high-quality research.

查看原文本刊更多论文

淋巴内免疫疗法对过敏性鼻炎有效且安全吗？一项荟萃分析。

背景：由于使用淋巴内免疫疗法（ILIT）作为过敏性鼻炎（AR）的治疗手段存在很多争议，因此本研究基于系统综述和荟萃分析对其治疗AR的有效性和安全性进行了调查：方法：采用 PubMed、Embase、Cochrane library 和 Web of Science 等数据库检索有关 ILIT 治疗 AR 的相关随机对照研究。检索截止日期为 2023 年 9 月 15 日。使用Stata 15.0对纳入文献的数据进行了元分析：结果：共纳入 11 项随机对照研究，涉及 406 名患者。Meta分析结果显示，与对照组相比，ILIT改善了患者的生活质量[标准化平均差（SMD）= -0.53，95%置信区间（CI）= (-1.00, -0.050)]，减少了鼻部症状的不良事件[风险比（RR）= 0.16，95% CI = (0.06, 0.45)]，而在症状评分方面没有发现显著差异[SMD = 0.14，95% CI = (-0.34, 0.62)]、IgE [SMD = 0.93，95% CI = (-0.44, 2.30)]、用药评分[SMD = 1.37，95% CI = (-0.45, 3.18)]、症状和用药综合评分[SMD = 0.93，95% CI = (-0.62，2.47)]、鼻部症状[RR = 0.16，95% CI = (0.06，0.45)]和淋巴结肿大[RR = 2.27，95% CI = (0.37，6.73)]：结论：应用ILIT策略治疗AR后，患者的生活质量得到改善，与鼻部症状相关的不良事件发生率降低，但这一结论还需要更多高质量的研究进一步验证。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Medicine 医学-医学：内科

CiteScore

2.80

自引率

0.00%

发文量

4342

审稿时长

>12 weeks

期刊介绍： Medicine is now a fully open access journal, providing authors with a distinctive new service offering continuous publication of original research across a broad spectrum of medical scientific disciplines and sub-specialties. As an open access title, Medicine will continue to provide authors with an established, trusted platform for the publication of their work. To ensure the ongoing quality of Medicine’s content, the peer-review process will only accept content that is scientifically, technically and ethically sound, and in compliance with standard reporting guidelines.